If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Block listing Interim Review

29 Sep 2016 15:00

RNS Number : 2209L
Vernalis PLC
29 September 2016
 

BLOCK LISTING SIX MONTHLY RETURN

 

VERNALIS PLC (the "Company")

 

29 September 2016

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP") and the Savings Related Share Option Plan 2003 ("SAYE")

Period of return (from / to):

From: 29/Mar/2016

To: 29/Sept/2016

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,243,318 Ordinary 1p Shares, split:

· Under LTIP = 2,243,318 Ordinary 1p Shares

· Under SAYE = NIL Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 1,074,958 Ordinary 1p Shares, split:

· Under LTIP = 1,074,958 Ordinary 1p Shares

· Under SAYE = NIL Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

767,304

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 401,056 Ordinary 1p Shares, split:

· Under LTIP = 401,056 Ordinary 1p Shares

· Under SAYE = NIL Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015

1,189,296

1 April 2016

 

 

-- ends -

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

 

David Mackney, Chief Financial Officer

 

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8000

Dr Julian Feneley

 

Henry Fitzgerald-O'Connor

 

Rupert Winckler

 

Emma Gabriel

 

 

Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

 

Toby Gibbs

 

 

FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

 

Simon Conway

 

Stephanie Cuthbert

 

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra®XR targeting the US prescription cough cold market; MOXATAG®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

 

For further information about Vernalis, please visit www.vernalis.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRLLMMTMBATBBF
Date   Source Headline
3rd May 20184:35 pmRNSPrice Monitoring Extension
27th Apr 20181:31 pmRNSForm 8.5 (EPT/RI)
20th Apr 20185:53 pmRNSHolding(s) in Company
20th Apr 20185:52 pmRNSHolding(s) in Company
20th Apr 20182:42 pmRNSForm 8.3 - Vernalis plc
20th Apr 201812:57 pmRNSHolding(s) in Company
20th Apr 201810:01 amRNSForm 8.3 - Vernalis Plc
20th Apr 201810:00 amRNSForm 8.3 - Vernalis PLC
18th Apr 20184:35 pmRNSPrice Monitoring Extension
17th Apr 20182:15 pmRNSForm 8.3 - Vernalis Plc
29th Mar 201810:08 amRNSPublic Opening Position Disclosure
29th Mar 20187:00 amRNSBlock Listing 6 Montly Return
28th Mar 20187:00 amRNSUnaudited Interim Results for 6 months to 31/12/17
22nd Mar 201810:47 amRNSForm 8.5 (EPT/RI)
21st Mar 20184:05 pmRNSRule 2.9 Announcement
21st Mar 20181:11 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20183:10 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20183:10 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20183:08 pmRNSForm 8.3 - Vernalis Plc
20th Mar 20182:42 pmRNSForm 8.3 - Vernalis PLC
19th Mar 20181:41 pmRNSForm 8.3 - Vernalis Plc
16th Mar 20182:47 pmRNSForm 8.3 - Vernalis plc
16th Mar 20182:25 pmRNSForm 8.5 (EPT/RI)
16th Mar 20181:00 pmRNSForm 8.3 - Vernalis Plc
16th Mar 201810:08 amRNSForm 8.3 - Vernalis Plc
15th Mar 20183:14 pmRNSForm 8.3 - Vernalis Plc
15th Mar 20187:00 amRNSUpdate on Strategic Review and Formal Sale Process
2nd Mar 20184:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20184:35 pmRNSPrice Monitoring Extension
1st Mar 20184:52 pmRNSHolding(s) in Company
28th Feb 20187:00 amRNSVernalis plc Trading and Corporate Update
8th Feb 20184:35 pmRNSPrice Monitoring Extension
29th Dec 20177:00 amRNSTotal Voting Rights
27th Dec 20174:40 pmRNSSecond Price Monitoring Extn
27th Dec 20174:35 pmRNSPrice Monitoring Extension
14th Dec 20171:15 pmRNSVernalis Results of Annual General Meeting
14th Dec 20177:00 amRNSAGM Statement
13th Dec 20177:00 amRNSVernalis + Daiichi Sankyo Enter Collaboration
6th Dec 20177:00 amRNSVernalis and Servier Achieve Research Milestone
5th Dec 20174:40 pmRNSSecond Price Monitoring Extn
5th Dec 20174:35 pmRNSPrice Monitoring Extension
30th Nov 201712:34 pmRNSTotal Voting Rights
2nd Nov 20177:00 amRNSNotice of Annual Report and AGM
31st Oct 20177:00 amRNSTotal Voting Rights
29th Sep 20177:00 amRNSBlock listing Interim Review
12th Sep 20177:00 amRNSResults Announcement for the Year Ended 30/06/2017
7th Aug 20177:00 amRNSFDA Issues Complete Response Letter on CCP-08 NDA
18th Jul 20177:00 amRNSYear-End Trading Update and Notice of Results
30th Jun 20177:00 amRNSTotal Voting Rights
31st May 20177:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.